Cytotoxicity of Gemcitabine-Loaded-Microemulsions in Breast and Colon Cancer Cells
Abstract
Purpose: To evaluate the antitumor activity of gemcitabine (GEM), incorporated in microemulsions with varying surfactant-to-oil (S/O) ratio, against MCF-7 breast cancer cells and HCT 116 colon cancer cells.
Methods: The microemulsion formulations consisted of Tween 80, Span 20, isopropyl myristate (IPM) and aqueous ethanol (40 %). Anticancer assessment involved determination of hemolysis activity, screening for cytotoxicity using sulphorhodamine B assay and determination of the mechanism of cell death using light microscope and ApopNexin FITC apoptosis detection kit.
Results: Hemolysis activity of all the microemulsion formulations, either blank or drug-loaded, was significantly less than that of GEM solution. On average, MCF-7 cell viability significantly (p < 0.05) decreased from 38.53 ± 6.04 to 30.1 ± 4.66 % when the administered microemulsion concentration in modified eagle medium (MEM), increased from 0.03 to 0.3 % v/v but significantly (p < 0.05) increased by 1.4-fold when exposed to GEM solution at equivalent concentrations. In contrast, the cytotoxicity of the microemulsion formulation against HCT116 cells was similar to that of 0.03 % v/v GEM solution but greater than that of GEM solution by 1.5-fold when their concentration in MEM increased to 0.3 %v/v. Microscopic studies show that the microemulsions stimulated apoptosis in MCF-7 and HCT116 cell within 48 h and at low concentration (0.03 %v/v).
Conclusion: Microemulsion formulations improved the efficacy of GEM and induced apoptosis in MCF- 7 and HCT116 cells.
Keywords: Apoptosis, MCF-7 breast cancer cells, HCT116 colon cancer cells, Hemolysis, Sulphorhodamine B assay, Microemulsion
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
